PLOS ONE ( IF 3.7 ) Pub Date : 2021-01-07 , DOI: 10.1371/journal.pone.0245149 Joaquín Barca 1, 2 , Ynte H Schukken 2, 3 , Ana Meikle 4
The objective of this study was to determine if parity affected the effect of pegbovigrastim (PEG) treatment on white blood cell (WBC) counts in grazing dairy cows. Additionally, the association of prepartum body condition score (BCS) and non-esterified fatty acid (Pre-NEFA) concentration with WBC counts was investigated. The effect of early-lactation disease was included in the statistical analysis. A randomized controlled trial on four commercial grazing dairy farms was performed. Holstein primiparous (Control = 87, PEG = 89) and multiparous (Control = 181, PEG = 184) cows were randomly assigned to one of two treatments: first PEG dose 8 ± 5 (mean ± SD) days before the expected calving date and a second dose within 24 h after calving (PEG) compared to untreated controls (Control). Treatment effects were evaluated with mixed linear regression models. Treatment with PEG increased WBC, neutrophil, lymphocyte and monocyte counts at 6 ± 1 (mean ± SD) days in milk. Parity, BCS and their interactions with treatment were not associated with WBC counts. In control cows, Pre-NEFA concentration was associated with reduced WBC, neutrophil and lymphocyte counts and tended to be associated with reduced monocyte counts. Pegbovigrastim treatment reversed the negative association of Pre-NEFA concentration with neutrophil and monocyte counts and tended to reverse the negative association of Pre-NEFA concentration with WBC counts. In the PEG treated group, cows diagnosed with retained placenta or metritis showed lower neutrophil counts when compared to PEG treated cows without these clinical diseases. These data confirm that PEG treatment increases WBC, neutrophil, lymphocyte and monocyte counts in grazing dairy cows and that this effect is independent of parity. Pegbovigrastim treatment reversed the negative association of Pre-NEFA concentration with neutrophil and monocyte counts, and tended to reverse the negative association of Pre-NEFA concentration with WBC counts.
中文翻译:
聚乙二醇化格司亭对初产和多产放牧奶牛白细胞计数的增加及其与产前身体状况评分和非酯化脂肪酸浓度的相互作用
本研究的目的是确定胎次是否影响聚乙二醇化格司亭 (PEG) 治疗对放牧奶牛白细胞 (WBC) 计数的影响。此外,还研究了产前身体状况评分(BCS)和非酯化脂肪酸(Pre-NEFA)浓度与白细胞计数的关系。早期哺乳疾病的影响被纳入统计分析中。对四个商业放牧奶牛场进行了随机对照试验。荷斯坦初产奶牛(对照 = 87,PEG = 89)和经产奶牛(对照 = 181,PEG = 184)被随机分配至两种处理之一:在预计产犊日期前 8 ± 5(平均值 ± 标准差)天首次 PEG 剂量,以及与未处理的对照 (Control) 相比,产犊后 24 小时内进行第二次给药 (PEG)。使用混合线性回归模型评估治疗效果。6 ± 1(平均值±标准差)天后,用 PEG 处理可增加牛奶中的白细胞、中性粒细胞、淋巴细胞和单核细胞计数。产次、BCS 及其与治疗的相互作用与 WBC 计数无关。在对照奶牛中,Pre-NEFA 浓度与白细胞、中性粒细胞和淋巴细胞计数减少有关,并且往往与单核细胞计数减少有关。Pegbovigrastim治疗逆转了Pre-NEFA浓度与中性粒细胞和单核细胞计数的负相关,并倾向于逆转Pre-NEFA浓度与WBC计数的负相关。在 PEG 治疗组中,与没有这些临床疾病的 PEG 治疗奶牛相比,被诊断患有胎盘滞留或子宫炎的奶牛表现出较低的中性粒细胞计数。这些数据证实,PEG 治疗增加了放牧奶牛的白细胞、中性粒细胞、淋巴细胞和单核细胞计数,并且这种效应与胎次无关。Pegbovigrastim治疗逆转了Pre-NEFA浓度与中性粒细胞和单核细胞计数的负相关,并倾向于逆转Pre-NEFA浓度与WBC计数的负相关。